SCHEMBL129672

SCHEMBL129672

CCc1cccc(C(C)(C)C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.53
CYP1A2 P05177 1/20 0.53
BCL2 P10415 1/20 0.47
KIF11 P52732 3/20 0.45
LTB4R Q15722 3/20 0.45
LTB4R2 Q9NPC1 3/20 0.45
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
PTGS2 P35354 1/20 0.43
TP53 P04637 1/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
HIF1A Q16665 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL129671 0.86 CYP2C19 (0.50) CYP2C19CYP1A2LTB4RLTB4R2CYP4F2
SCHEMBL1124987 0.86 CYP2C19 (0.50) CYP2C19CYP1A2LTB4RLTB4R2CYP4F2
SCHEMBL31477275 0.84 CYP2C19 (0.49) CYP2C19CYP1A2LTB4RLTB4R2CYP4F2
SCHEMBL289829 0.84 PPARA (0.59) CYP2C19CYP1A2CYP4F2CYP4A11
SCHEMBL15067657 0.80 NPC1 (0.46) CYP2C19CYP1A2LTB4RLTB4R2CYP4F2
SCHEMBL15678404 0.79 CYP2C19 (0.50) CYP2C19CYP1A2BCL2KIF11PTGS2
SCHEMBL127737 0.79 ALDH1A1 (0.52) KIF11TP53MAPTKMT2ASMN1; SMN2
SCHEMBL1643008 0.77 HSD17B1 (0.53) CYP2C19CYP1A2KIF11MAPTKMT2A
SCHEMBL1653535 0.77 KIF11 (0.45) CYP2C19KIF11MAPTKMT2ASMN1; SMN2
Acetic Acid SCHEMBL3077099 0.76 ACP3 (0.56) MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714240-B2 Vinyl autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-07-25 US disclosed
US-8450319-B2 Pyrrolopyridazinone compound UBE INDUSTRIES, LTD. (JP) 2013-05-28 US disclosed
EP-1982986-B1 PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR UBE INDUSTRIES (JP) 2012-03-07 EP disclosed
WO-2011025565-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 WO disclosed
US-20110028499-A1 PHARMACEUTICAL COMBINATION COMPRISING VITAMIN K SHIONOGI & CO., LTD. (JP) 2011-02-03 US disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028499-A1 PHARMACEUTICAL COMBINATION COMPRISING VITAMIN K PPARD, PROC, VDR CYP2C19 302/4885CYP1A2 847/4885BCL2 3386/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 CYP2C19 44/4885CYP1A2 84/4885BCL2 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.